



Office de la Propriété
Intellectuelle
du Canada

Un organisme
d'Industrie Canada

Canadian
Intellectual Property
Office

An agency of
Industry Canada

CA 2655733 A1 2008/01/03

(21) **2 655 733**

(12) **DEMANDE DE BREVET CANADIEN
CANADIAN PATENT APPLICATION**

(13) **A1**

(86) Date de dépôt PCT/PCT Filing Date: 2007/06/28
(87) Date publication PCT/PCT Publication Date: 2008/01/03
(85) Entrée phase nationale/National Entry: 2008/12/17
(86) N° demande PCT/PCT Application No.: EP 2007/056465
(87) N° publication PCT/PCT Publication No.: 2008/000789
(30) Priorité/Priority: 2006/06/29 (ITFI2006A000163)

(51) Cl.Int./Int.Cl. *A61K 39/39* (2006.01),
A61K 39/395 (2006.01)
(71) Demandeur/Applicant:
MENARINI INTERNATIONAL OPERATIONS
LUXEMBOURG S.A., LU
(72) Inventeurs/Inventors:
FLEMMING, JENS, DE;
GROEGER, KARSTEN, DE;
SCHMITZ, REINHARD, DE;
MANZINI, STEFANO, IT
(74) Agent: BERESKIN & PARR LLP

(54) Titre : COMPOSITIONS PHARMACEUTIQUES CONTENANT UN ANTICORPS MONOCLONAL ANTI-IDIOTYPIQUE
ANTI-CA-125 ET DE L'ALUMINIUM
(54) Title: PHARMACEUTICAL COMPOSITIONS CONTAINING MONOCLONAL ANTI IDIOTYPIC ANTI-CA-125
ANTIBODY AND ALUMINIUM

(57) **Abrégé/Abstract:**

The present invention refers to a pharmaceutical composition for parenteral administration as vaccine comprising a monoclonal antibody and as adjuvant an aluminium derivative.



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
3 January 2008 (03.01.2008)

PCT

(10) International Publication Number
WO 2008/000789 A3

(51) International Patent Classification:

A61K 39/39 (2006.01) A61K 39/395 (2006.01)

(21) International Application Number:

PCT/EP2007/056465

(22) International Filing Date: 28 June 2007 (28.06.2007)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

FI2006A000163 29 June 2006 (29.06.2006) IT

(71) Applicant (*for all designated States except US*): **MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG S.A.** [LU/LU]; 1, Avenue de la Gare, L-1611 Luxembourg (LU).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **FLEMMING, Jens** [DE/DE]; Küsterkamp 33, 22041 Hamburg (DE). **GRÖGER, Karsten** [DE/DE]; Wisslerstrasse 23, 12587 Berlin (DE). **SCHMITZ, Reinhard** [DE/DE]; Flatowallee 21, 14055 Berlin (DE). **MANZINI, Stefano** [IT/IT]; Via della Mattonaia 25, I-50121 Firenze (IT).

(74) Agents: **GERVASI, Gemma** et al.; Corso di Porta Vittoria 9, I-20122 Milan (IT).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM,

AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
— with sequence listing part of description published separately in electronic form and available upon request from the International Bureau

(88) Date of publication of the international search report:

28 February 2008

(54) Title: PHARMACEUTICAL COMPOSITIONS CONTAINING MONOCLONAL ANTI IDIOTYPIC ANTI-CA-125 ANTIBODY AND ALUMINIUM DERIVATIVES

(57) Abstract: The present invention refers to a pharmaceutical composition for parenteral administration as vaccine comprising a monoclonal antibody and as adjuvant an aluminium derivative.



WO 2008/000789 A3

PHARMACEUTICAL COMPOSITIONS CONTAINING MONOCLONAL ANTI IDIOTYPIC ANTI-CA-125 ANTIBODY AND ALUMINIUM

Field of the application

The invention refers to the field of pharmaceutical compositions to be used as vaccine for
5 parenteral application.

State of the art

As it is known, in order to amplify the immunogenicity of prophylactic or therapeutic vaccines the use of adjuvant, such as an aluminium compound, is generally considered (Fiejka et al., Rocz Panstw Zakl Hig 1993, 73 - 80) in the preparation of pharmaceutical
10 dosage forms as solutions or suspensions for parenteral administration. The target of these formulations should be inducing a maximal and long-lasting immunogenic effect.

However a limited amount of aluminium adjuvants have been up to now used in registered and marketed vaccine and indeed a limit of 1.25 mg/dose is established in Ph.Eur.

Also FDA in the 21 CFR 610.15 states the amount of aluminium in the recommended
15 individual dose of a biological product shall not exceed:

- (1) 0.85 milligrams if determined by assay; or
- (2) 1.14 milligrams if determined by calculation on the basis of the amount of aluminium compound added; or
- (3) 1.25 milligrams determined by assay provided that data demonstrating that the
20 amount of aluminium used is safe and necessary to produce the intended effect.

The immunogenicity of antibodies adsorbed onto aluminium adjuvants appears to depend on the degree of adsorption (Capelle et al., Vaccine 2005, 1686 - 1694), but it is unclear which is the best ratio to be used to achieve a maximal immunogenic response still maintaining a safety profile. For instance, the World Health Organisation (WHO)
25 recommends an adsorption onto aluminium adjuvants at toxoid levels exceeding 80 % for tetanus and diphtheria toxoids (Gupta et al., Vaccine 1995, 1263 - 1276; WHO Technical Report Series No. 595, 1996, p. 6). In contrast, data show that an adsorption of tetanus components to aluminium hydroxide of levels exceeding 80 % did not enhance the immune response in healthy adults (Paoletti et al., Infect Immun 2001, 6696 - 6701). The
30 most appropriate content of an aluminium compound to maximise the immunogenicity (without risk of unacceptable toxic side effect) of a monoclonal antibody-containing vaccine is still an open technical question.

Another technical issue is the stability of vaccines that varies considerably. They can be ranked by their resistance to storage at elevated temperatures, with diphtheria and tetanus toxoids and hepatitis B vaccine showing the highest thermostability, freeze-dried measles, yellow fever and BCG vaccine occupying the middle position and oral poliomyelitis vaccine being the most fragile (Galazka et al., Thermostability of vaccines, World Health Organisation, 1998). Reconstituted vaccines against measles, yellow fever and tuberculosis (BCG) are unstable vaccines; they should be used as soon as possible after the reconstitution and be kept in an ice bath during immunisation session. Although tetanus and diphtheria (e.g. adsorbed on aluminium salts) as monovalent vaccines or components of combined vaccines are stable for weeks at 35 –37° C, each exposure to ambient temperature results in some degradation of the vaccine (Galazka et al, vide supra , pag 48). Therefore also for these “stable” types of vaccines the storage at cold conditions is prescribed (Rote Liste, Edition Cantor Verlag, 2005).

An unsolved technical issue for this type of vaccine containing monoclonal antibodies, is the low stability at ambient temperatures.

Due to the nature of the complex protein active principle, these drug products have to be stored under cold conditions (2 - 8 °C) requiring a constant cooling chain. This causes higher distribution costs, jeopardise the overall safety profile and, possibly more important, limits the world-wide use of highly beneficial drugs like an anticancer vaccine. The development of vaccine formulations ensuring constant drug product quality even at ambient and higher temperatures (25°C – 37 °C) would therefore improve the overall safety and efficacy profile of these drugs. This would not only be highly beneficial for patients, but would also lead to an overall facilitated handling of these valuable drugs.

On the other hand the importance of immunotherapy in the treatment of tumours in humans and in particular the use of monoclonal anti idiotypic antibodies as therapeutic vaccines against tumours is well known.

Such vaccine should activate the immunity system in the host stimulating a humour and cell action against the tumour.

The development and definition of such a kind of formulation is particularly important for ACA125/MEN2234 (described in EP700305), a very promising anti-idiotypic monoclonal antibody intended to be used as a therapeutic vaccine against ovarian carcinoma. To MEN2234 the following CA Index Name was assigned: immunoglobulin G1, anti-(mouse

OC 125) (mouse monoclonal ACA-125clone 3D5 g-chain), disulfide with mouse monoclonal ACA-125 clone 3D5 k-chain, dimer. The corresponding CAS Registry Number is 792921-10-9. The proposed INN is Abagovomab

The amino acid sequence of MEN 2234 is shown hereinafter.

5 MEN 2234 is a murine monoclonal antibody generated against the murine monoclonal antibody OC125, that recognises the tumour associated antigen (TAA) CA125. MEN 2234 effectively mimics the tri-dimensional structure of CA125 TAA and so induce in the host the production of anti-anti-idiotypic antibodies (Ab3) targeting the tumour cells expressing the CA125 antigen. MEN 2234 is also able to elicit in the host a cellular immune response
10 specifically directed against CA125 tumour cells.

Approximately 80 % of patients with advanced ovarian cancer have elevated expression of CA125. Although CA125 is over-expressed in ovarian cancer, the human organism itself is not capable to mount an effective immune response against these cancer cells. The treatment with a therapeutic vaccine containing MEN 2234 should instead be able to re-
15 awakening the immune system of the host to attack and destroy disseminated ovarian cancer cells.

EP700305 described the monoclonal anti-idiotypic anti-CA125 antibodies, but no specific pharmaceutical formulation suitable for the treatment of pathologies is described.

In Hybridoma, 1995, 14 (2), 164-174, the antibody ACA-125 was characterised, but no
20 formulation was developed.

In Clinical Cancer Research, 2004, 10, 1580-1587 vaccination of patients with ACA125 was performed; no indication on the concentration of aluminium in the formulation was disclosed, but a man skilled in the art, based on prior art, could easily imagine a relatively low concentration of aluminium as adjuvant (lower than 1.25 mg per individual dose).

25 In Hybridoma, 2005, 133-140, is described a delivery system for continuous endogenous release of ACA125hFc (a chimeric form of ACA 125) to improve its immunogenicity as vaccine against ovarian cancer, but they generated an in vitro depot based on bioencapsulation technology.

Further publication summarises the results of pre-clinical and clinical studies on ovarian
30 cancer vaccines incl. MEN2234 but concrete data on formulation or used concentration of adjuvants are not mentioned (e.g. an aluminium compound is not cited) : Clinical Cancer

Research, 2004, 1580-1587; Clinical Cancer Research, 2003, 3234-3240; Clinical Cancer Research, 2001, 1154-1162; Clinical Cancer Research, 2001, 1112-1115).

Detailed Description of the Invention

The invention claims a pharmaceutical formulation for parenteral application (preferably
5 subcutaneous or intramuscular) containing the monoclonal anti-idiotypic antibody
MEN2234 adsorbed onto an aluminium compound selected among aluminium hydroxide
(alum) or aluminium phosphate, and suspended in an aqueous buffered system.

The use of high concentrations (well above those usually considered and recommended) of
an aluminium compound as adjuvant provides a vaccine with unexpected clinical and
10 pharmaceutical advantages such as:

- I. guarantee of an extraordinary high specific immunogenicity for both humoral and cellular responses
- II. guarantee of a long-lasting induction and maintenance of an immune response
- III. guarantee of safety drug administration ;
- 15 IV. simplification of manufacturing and release procedure for the final drug product;
- V. increased consistency in the manufacturing processes
- VI. improvement of drug product stability also at relevant temperature ranges.

Pharmaceutical compositions according to the present invention contain the anti-idiotypic antibody MEN2234 in an amount from 0.1 mg/ml to 4 mg/ml, preferably 0.2mg/ml to 2.5
20 mg/ml, even more preferably in a concentration approximately of 2 mg/ml (from 1.9 to 2.1 mg/ml). The antibody MEN2234 is adsorbed onto an aluminium compound (preferably at a concentration of approximately 3.5 mg/ml of aluminium) and suspended in a buffered and isotonic saline solution . The present compositions do not need any other ingredient in addition to the antibody adsorbed onto the aluminium compound and the salts of the
25 buffers , resulting in a very simple solution devoid of any additional safety concerns which could derive from the use of other agents such as stabilisers, antioxidants, other adjuvants etc..

Preferred buffers are those obtained with phosphate or citrate salts.

Final composition contains preferably 1 ml of the product to be administered parenterally,
30 preferable via subcutaneous or intramuscular injections.

One of the main characteristic of the present invention is that a relatively high concentration of an aluminium compound, selected among aluminium phosphate and

aluminium hydroxide, is required to ensure a nearly complete adsorption of MEN2234 onto the adsorbent; aluminium hydroxide being highly preferred (ref. Table 1).

The preferred concentration of aluminium Al^{+++} in the compositions is in the range 2.4-5.2 mg/ml, most preferably approximately 3.5 mg/ml (in the range 3.1-3.8 mg/ml). which corresponds to a content in aluminium hydroxide in the range 0.7 –1.5% W/W, preferably approximately 1% W/W (in the range 0.9-1.1 %)

Table 1: Dependency of MEN2234 adsorption (non-adsorbed protein) on aluminium concentration (aluminium hydroxide)

Concentration		Non-adsorbed protein [%]
Al^{+++} [mg/ml]	$Al(OH)_3$ [%]	
0	0	100
0.9	0.25	78
1.2	0.36	59
1.7	0.5	30
2.6	0.75	<1.0
3.5	1.0	<0.1
6.9	2.0	<0.1

The content of aluminium hydroxide 1% corresponds to approx. 3.5 mg aluminium Al^{+++} per ml, so well above the content currently used in the registered and marketed vaccines and generally recommended by the authorities.

The present formulations could be prepared according to standard procedures well known in the art. A general procedure that can be used is as follow. The manufacturing of the final product will be performed by mixing the antibody solution and the adjuvant (a gel of aluminium compound) under defined conditions. The drug product has to meet the sterility requirements according to Ph. Eur. Monograph "Parenteral preparation". Consequently, according to the regulatory requirements the manufacturing process will be carried out strictly under aseptic conditions. All used ingredients are sterile grade or are filtered through a 0.22 micrometer filter in form of a solution during manufacturing.

Formulations according to the present application show a consistent group of advantages:

I. Guarantee of an extraordinary high specific immunogenicity for both humoral and cellular response

We have demonstrated that the monthly treatment (four weekly s.c. administration) of the composition matter of the present invention is able to induce a specific humoral response (specific antibody directed against MEN2234) in an amount dependent on the concentration of the aluminium compound. In fact it has been show that the amount of humoral response elicited by the formulation with 1% aluminium hydroxide (Example 1) is significantly superior to that elicited by a suspension containing 0.36 % aluminium hydroxide (corresponding to the limit indicated by Ph.Eur, and FDA guidelines) or by a solution of MEN2234 in buffered saline:

Table 2: Plasma titers of antibodies against MEN2234 measured in rabbit plasma following 4 weekly s.c. administrations

Formulation	Antibody titer (ng/ml)
MEN 2234 solution	907 $\pm$ 259
MEN 2234 suspension in Al(OH) ₃ at 0.36 %	3658 $\pm$ 1473
MEN 2234 suspension in Al(OH) ₃ at 1.0 %	15627 $\pm$ 5007 *

* P<0.05 vs the other two conditions (Bonferroni Multiple Comparison Test)

15

In addition an histological assessment was carried out at the injection sites to measure the recruitment of inflammatory cells and antigen-presenting cells necessary for the establishment of a specific cellular immune response. Also for this parameter the response to the formulation with 1% aluminium hydroxide (Example 1) was remarkably superior to that achieved with a suspension at lower Al(OH)₃ content (0.36%) or a MEN2234 solution without Al(OH)₃:

20

Table 3: Semiquantitative detection of inflammatory cells in the injection sites of rabbit weekly treated with the vaccines

Formulation	Density of inflammatory cells
MEN 2234 solution	+/-
MEN 2234 suspension in Al(OH) ₃ at 0.36 %	++
MEN 2234 suspension in Al(OH) ₃ at 1.0 %	+++

5 II. Guarantee of a long-lasting induction and maintenance of an immune response

In the rabbit we have demonstrated that following the immunisation (4 weekly injections) with the composition matter in Example 1, the immune response is maintained for a longer time and even after several weeks specific antibodies are measurable in the plasma. On the other hand when the immunisation is done with MEN2234 suspension with a lower
10 amount of Al(OH)₃ (0.36 %) or with MEN2234 as a solution without adjuvant, the presence of antibodies is detectable for a shorter period of time:

III Guarantee of safety drug administration

The MEN2234 suspension matter of this invention has been administered , as s.c. injections at the dose of 2 mg/ml, up to 26 weeks in the rabbit. The scheme of
15 administration was weekly in the first month and then bi-weekly in the remaining period. Local tolerance and systemic safety was assessed. Even after 15 treatments no toxic effects was recorded in terms of: body weight, clinical signs, food consumption, haematology, clinical chemistry, histopathology of all organs. At the site of injections only the inflammatory and immunological response as consequence of the pharmacological action
20 of the drug was observed.

In addition this invention, allowing a reduced amount of free murine antibody, will also decrease its absorption and peak in the systemic circulation thus reducing the risk of anaphylactic reaction(s).

IV Simplification of manufacturing and release procedure for the final drug product

25 Approximately 1 % aluminium hydroxide ensures complete MEN2234 binding (<1% non adsorbed antibody). This results in a very robust adsorption and manufacturing process avoiding the need of in-vivo release tests (immunogenic response in experimental animals)

as usually required for many aluminium containing vaccines like tetanus, diphtheria. The complete adsorption guarantee an optimal antibody (Ab2) presentation to the host immune system..

Detailed investigations of the MEN2234 - aluminium hydroxide adsorption mechanism revealed that a nearly ideal stoichiometric distribution of both substances is achieved in a phosphate buffer solution. This ensures, as mentioned before, a simple and robust manufacturing process due to the self assembling properties of the invention. Already after 15 sec moderate mixing the antibody is nearly complete adsorbed onto aluminium hydroxide (Table 4).

Table 4: Dependency of MEN2234 adsorption on mixing time (aluminium hydroxide concentration 1%)

Mixing time [min:sec]	Non-adsorbed protein [%]
0	100
0:10	0.20
0:30	0.20
1:00	0.15
5:00	0.20
15:00	0.03
240:00	0.10

As seen in Table1, with concentration of adjuvant minor than 0.75% no complete adsorption could be achieved; concentrations higher than 1% (e.g. 2%) did not show any improvement.

The very quick and complete adsorption of MEN2234 onto aluminium compound at higher concentrations of the adsorbent than recommended allows to remarkably simplify the manufacturing of the composition as a drug. Within seconds the final formulation is

obtained simply by mixing the monoclonal antibody with the adjuvant. This mixing step can be performed routinely by using standard equipment for aseptic processing at pharmaceutical facilities. The self-assembling characteristics of the described system leads to completely new perspectives in manufacturing and stabilising of the present formulation as well as for adsorbed monoclonal antibodies or vaccines in general. The complete adsorption of MEN2234 onto the aluminium adjuvant within seconds could also allow the preparation of the final suspension immediately before s.c. or i.m. injection only by mixing the required amounts of drug substance and aluminium adjuvant at the site of final application to patients, e.g. at the hospital.

Therefore a particular aspect of the present invention is represented by a form where the active principle of the vaccine (the antibody MEN2234) and the adjuvant (the aluminium compound, preferably aluminium hydroxide) are kept separated and ready to be mixed just prior of the injection to the patient. The preferred time for this mixing step should be between 10 seconds and 10 minutes before the administration to the patient.

For this particular form, the composition should be provided with the antibody and the adjuvant solution separated each other but filled in pharmaceutical standard container systems like vials, ampoules, pre-filled syringes or appropriate two-chamber systems for mixing and/or reconstitution. The monoclonal antibody can not only be used in form of a eventually buffered solution but also in form of e.g. a powder. The possibility to use the drug substance in solid form allows to apply for it all techniques intended to improve the stability of monoclonal antibodies or vaccines (freeze-drying, spray drying etc.). This represents a significant progress in handling and an improvement in stability for all adsorbed vaccines in general and, in particular, for those containing monoclonal antibodies such as MEN 2234. Main disadvantages of adsorbed vaccines like a permanent cooling chain during shipment and storage, can be avoided and the shelf life of the drug product can be increased.

As mentioned, the in vivo immunogenic activity of monoclonal antibodies containing pharmaceutical compositions depends in a variable manner on the degree of adsorption of the antibody onto the used adsorbents (Capelle et al., Vaccine 2005, 1686 - 1694).

Therefore it is state of the art to determine the biological immunogenic activity of (adsorbed) vaccines 'in vivo' in animals prior of the drug product release. The reproducible adsorption of MEN 2234 onto the aluminium adjuvant simplifies the release procedure

significantly. Due to the reliability of adsorption, release testing could recourse only on in vitro testing to determine the potency of the composition. The usual procedure to determine also the 'in vivo' biological activity in animals is, for the composition of the present invention, redundant.

5 V. Improvement of consistency in drug product manufacturing

The reproducibility in MEN 2234 adsorption using higher concentrations of e.g. aluminium hydroxide than recommended improves significantly the consistency in drug product manufacturing. As demonstrated in Table 5 if the concentration of aluminium hydroxide in the formulations is in the range 0.7 to 2 % w/v the adsorption of MEN 2234 is
10 complete (< 1 % free antibody) for all batches manufactured.

Table 5: Variability of MEN 2234 adsorption (non-adsorbed antibody) on aluminium hydroxide during manufacturing

Concentration aluminium hydroxide [%]	Non-adsorbed antibody [%]	
	Run I	Run II
0	100	100
0.25	78	36
0.36	59	11
0.5	30	6
0.75	< 1.0	< 1.0
1.0	< 0.1	< 0.1
2.0	< 0.1	< 0.1

15 The complete and reproducible adsorption prevents furthermore feared complications during processing such as the formation of antibody agglomerates. Antibodies in solution are susceptible to form aggregates. Aggregation of antibodies in solution can be induced by excessive shear forces in the liquid phase for example during agitation. These aggregates cannot be re-dissolved and leads to a significant reduction of the biological activity of the

vaccine. However, due the complete and rapid adsorption process this phenomenon can be avoided totally for the compositions object of the present invention.

VI. Improvement of drug product stability also at relevant temperature ranges

Surprisingly, composition of example 1 is by far more stabile (even by 25 °C and 37 °C) in comparison to the buffered MEN2234 solution. This simple but very effective mean (the increase in the aluminium hydroxide concentration up to 2 or 3 fold of the recommended dose) ensures nearly complete binding and accordingly also stability. In Table 6 relevant stability data are presented for MEN2234 in solution and formulated according to example 1.

Table 6: Stability data for MEN2234 in solution and adsorbed onto aluminium hydroxide

Test product	Storage condition [°C]	Product [%] after time of storage (months)		
		0	1	2
MEN2234 solution, batch K2CL73-P5	25	100.0	90.2	88.6
	37	100.0	88.9	89.1
MEN2234 adsorbed onto 1 % aluminium hydroxide, batch 287- 2p42	25	100.0	102.1	98.7
	37	100.0	98.7	100.4

Consequently, the invention ensures the required antibody stability and activity at relevant body temperatures (36 - 37 °C) after administration in humans.

Examples

Non limiting examples of the invention are the following:

Example 1: suspension for injection

Ingredient	mg/ml
MEN2234	2.00
Al(OH) ₃ *	10.00
5 KCl	0.20
KH ₂ PO ₄	0.20
NaCl	8.00
Na ₂ HPO ₄ x 7 H ₂ O	2.16
Water for injections	ad 1.00 ml

10 * used for manufacturing aluminium hydroxide, hydrated, for adsorption

The composition was prepared according to standard procedure, as previously described, simply mixing MEN2234 with a suspension of aluminium hydroxide, hydrate, in a solution buffered with the relevant salts.

Example 2: suspension for injection

15	Ingredient	mg/ml
	MEN2234	2.00
	Al(OH) ₃ *	7.50
	KCl	0.20
	KH ₂ PO ₄	0.20
20	NaCl	8.00
	Na ₂ HPO ₄ x 7 H ₂ O	2.16
	Water for injections	ad 1.00 ml

* used for manufacturing aluminium hydroxide, hydrated, for adsorption

Prepared as for example 1

25 Example 3: suspension for injection

	Ingredient	mg/ml
	MEN2234	2.00
	AlPO ₄	10.00
	KH ₂ PO ₄	0.20
30	NaCl	9.00
	Na ₂ HPO ₄ x 7 H ₂ O	1.20
	Water for injections	ad 1.00 ml

Prepared as for example 1

Example 4: Amino-acid sequence determination of MEN2234 (abagovomab).

SEQ. ID NO. 1

5 Heavy chain sequence
 QVQXQQSGAE XARPGASVKX SCKASGYTFT NYWMQWVKQR PGQGXDWXGA XYPGDGNTRY 60
 TQKFKGKATX TADKSSSTAY MQXSSXASED SAVYYCARGE GNYAWFAYWG QGTXTVTSAA 120
 KTTPPSVYPX APGSAAQTNS MVTXGCXVKG YFPEPVTVTW NSGSXSSGVH TFPVXQSDX 180
 YTXSSSVTVP SSTWPSETVT CNVAHPASST KVDKKXVPRD CGCKPCXCTV PEVSSVFXFP 240
 10 PKPKDVXTXT XTPKVTCVVV DXSKDDPEVQ FSWFVDDVEV HTAQIQPREE QFNSTFRSVS 300
 EXPXMHQDWX NGKEFKCRVN SAAFPAPXEK TXSKTKGRPK APQVYTXPPP KEQMAKDKVS 360
 XTCMXTDFFP EDXTVEWQWN GQPAENYKNT QPXMDTDGSY FVYSKXNVQK SNWEAGNTFT 400
 CSVXHEGXHN HHTKXSXSHS PGK

15 SEQ. ID NO.2

Light chain sequence
 DIQMTQSPAS LSASVGETVT XTCRASENXY SYXAWHQKQ GKSPQXXVYN AKTXAGGVSS 60
 RFSGSGSGTH FSXKXKSXQP EDFGXYYCQH HYGXFPTFGG GTKXEXKRAD AAPTVSXFPP 120
 20 SSEQXTSGGA SVVCFXNNFY PKDXNVKWKX DGSERQNGVX NSWTDQDSKD STYSMSSTXT 180
 XTKDEYERHN SYTCEATHKT STSPXVKSFN RNEC

A first part of the amino-acid sequence determination in abagovomab was accomplished
 25 using the automatic sequencing techniques according to Edman degradation procedure, in a
 protein sequencer where abagovomab was covalently linked to the sequencing membrane
 (first 15 amino acids of the light chain).

As automated Edman sequencing was not able to produce any sequence data of the heavy
 chain, suggesting a modification of the N-terminal group of the heavy chain to
 30 pyroglutamic acid, for a more extended sequencing, the well known LC/MS/MS
 sequencing techniques were used utilising mass spectrometry (e. g.. Proc. Natl Acad Sci
 USA, 1986 Sep Sep, 83(17), 6233-6237).

Briefly, different antibody samples were fragmented with different proteolytic enzymes
 before LC/MS/MS analysis and yielded several series of overlapping sequence fragments.
 35 By finding the overlapping scheme of these fragments, it was possible to determine the
 total sequence of the light chain of the antibody (complete amino acid sequences of the
 heavy and light chain are shown in SEQ. ID NO. 1 and SEQ. ID NO. 2).

As a final check for the reliability of the experimental results, the sequences reported were
 also verified by sequence similarity analysis with the BLAST software package against a
 40 non redundant protein database optimized for protein analysis (MSDB, download of March
 2007 from the European Bioinformatics Institute ftp site).

Since in mass spectrometry it is impossible to distinguish between isoleucine and leucine, in figure 1 this indecision is represented with “X”.

CLAIMS

- 1) Pharmaceutical composition for parenteral administration as vaccine comprising a monoclonal antibody and as adjuvant an aluminium derivative in concentration
 5 comprised between 2.4 and 5.2 mg/ml aluminium ion wherein:
 - said monoclonal antibody is the monoclonal anti idiotypic anti-CA-125 MEN 2234 comprising SEQ. ID NO. 1 and SEQ ID NO. 2 and is present in an amount from 0.1- 4 mg/ml; and
 - said aluminium compound is chosen among aluminium hydroxide and aluminium
 10 phosphate.
- 2) Pharmaceutical composition according to Claim 1 wherein the aluminium derivative is in concentration comprised between 3.1 – 3.8 mg/ml of aluminium ion.
- 3) Pharmaceutical composition according to claim 2, wherein the aluminium compound is aluminium hydroxide
- 15 4) Pharmaceutical composition according to claims 3 wherein the MEN2234 is present in an amount from 0.2 – 2.5 mg/ml
- 5) Pharmaceutical composition according to claim 4, wherein MEN2234 is present in an amount from 1.9 to 2.1 mg/ml
- 6) Pharmaceutical composition according to claims 1-5, wherein MEN2234 is adsorbed
 20 onto the aluminium compound and suspended in a buffered and isotonic saline solution.
- 7) Pharmaceutical composition according to claims 1-6, in the form of a liquid suspension, suitable for parenteral administration.
- 8) Pharmaceutical composition according to claims 7, suitable for subcutaneous or
 25 intramuscular administration
- 9) Pharmaceutical composition according to Claims 1 – 8, selected among the following:
 - a) MEN2234 2.00 mg/ml, $\text{Al}(\text{OH})_3$ 10.00 mg/ml, KCl 0.20 mg/ml, KH_2PO_4 0.20 mg/ml, NaCl 8.00 mg/ml, $\text{Na}_2\text{HPO}_4 \cdot 7 \text{H}_2\text{O}$ 2.16 mg/ml, Water for injections up to 1.00 m
 - b) MEN2234 2.00 mg/ml, $\text{Al}(\text{OH})_3$ 7.50 mg/ml, KCl 0.20 mg/ml, KH_2PO_4 0.20 mg/ml,
 30 NaCl 8.00 mg/ml, $\text{Na}_2\text{HPO}_4 \cdot 7 \text{H}_2\text{O}$ 2.16 mg/ml, Water for injections up to 1.00 m
 - c) MEN2234 2.00 mg/ml, AlPO_4 10.00 mg/ml, KH_2PO_4 0.20 mg/ml, NaCl 9.00 mg/ml, $\text{Na}_2\text{HPO}_4 \cdot 7 \text{H}_2\text{O}$ 1.20 mg/ml, Water for injections ad 1.00 ml

- 10) Pharmaceutical composition according to claims 1-9 to be used as antitumoral vaccine for the treatment or the prevention of tumours.
- 11) Pharmaceutical composition according to claim 10 as antitumoral vaccine for the treatment of ovarian tumours.